Company Chongqing Lummy Pharmaceutical Co., Ltd.

Company Chongqing Lummy Pharmaceutical Co., Ltd.

300006

CNE100000H10

Pharmaceuticals

Equities

300006

CNE100000H10

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Other Pharmaceuticals

CHONGQING LUMMY PHARMACEUTICAL CO., LTD.

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 13/05/2024 am IST			5-day change	1st Jan Change
2.91 ^CNY	-3.00%		-1.69%	-21.77%

23/04	Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
22/03	Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Chongqing Lummy Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of medicines. The Companyâs medicines consist of anti-infection medicines, special medicines, infusion, Chinese patent drugs and herbal decoction pieces. The Company's main products include carbon nanoparticles suspension injection, omeprazole enteric capsules, mycobacterium phlei F.U.36 injection, levofloxacin hydrochloride and tranexamic acid and sodium chloride injection, among others. The Company distributes its products in domestic market.

Number of employees: 800

CNY in Million	2022	Weight	2023	Weight	Delta
Specialties 67.4 %	637	72.0 %	604	67.4 %	-5.25%
Medicine Distribution 13.4 %	93	10.5 %	120	13.4 %	+28.57%
Anti-infection 13.3 %	113	12.8 %	119	13.3 %	+5.55%
Other Business 2.4 %	19	2.2 %	21	2.4 %	+11.59%
Other Varieties 1.8 %	3	0.4 %	16	1.8 %	+396.92%
Service Income 1.7 %	19	2.1 %	15	1.7 %	-18.03%

CNY in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	885	100.0 %	896	100.0 %	+1.24%

Managers	Title	Age	Since
Rong Zhao Qiu CEO	Chief Executive Officer	30	12/20/12
Wen Lai DFI	Director of Finance/CFO	50	01/03/01
Yuan Yuan CHM	Chairman	42	01/11/01
Hui Chuan Xu CTO	Chief Tech/Sci/R&D Officer	46	01/07/01
Xue Feng Leng BRD	Director/Board Member	52	-
Dan Cui IRC	Investor Relations Contact	44	01/10/01

Members of the board	Title	Age	Since
Xue Feng Leng BRD	Director/Board Member	52	-
Zhang Bi Li BRD	Director/Board Member	52	13/20/13
Hui Chuan Xu CTO	Chief Tech/Sci/R&D Officer	46	01/07/01
Xu Jiang Chen BRD	Director/Board Member	51	12/20/12
Yuan Yuan CHM	Chairman	42	01/11/01
Geng Chen BRD	Director/Board Member	51	12/20/12
Jiansheng Liang CHM	Chairman	42	30/21/30
Ri Hua Ou BRD	Director/Board Member	48	12/20/12
Ming Yue Tan BRD	Director/Board Member	31	01/19/01
Hai Run Wang BRD	Director/Board Member	36	16/23/16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,055,911,205	343,160,293 ( 32.50 %)	0	32.50 %

Name	Equities	%	Valuation
China Southern Asset Management Co., Ltd. 0.2243 %	1,821,700	0.2243 %	729 536 ¥
GF Fund Management Co., Ltd. 0.002179 %	17,700	0.002179 %	7 088 ¥
CCB Principal Asset Management Co., Ltd. 0.000296 %	2,400	0.000296 %	961 ¥
Truvalue Asset Management Co. Ltd. 0.000271 %	2,200	0.000271 %	881 ¥

Chongqing Lummy Pharmaceutical Co., Ltd.

15-16/F, Building B Chongqing Institute of Sci & Tech

401121, Chongqing

+86 23 6730 0382

http://www.cqlummy.com

address Chongqing Lummy Pharmaceutical Co., Ltd.(300006)

	1st Jan change	Capi.
CHONGQING LUMMY PHARMACEUTICAL CO., LTD.	-21.77%	425M
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+31.69%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.47%	240B
NOVARTIS AG	+9.34%	209B
ROCHE HOLDING AG	-9.24%	203B
AMGEN INC.	+7.09%	165B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals